I think we’ve progressed from an era of knowing diseases like chronic myeloid leukemia, where you have a specific Philadelphia chromosome positive driven disease which is present in 95% of the disease, it’s really looking at more patients on an individual basis and figuring out and what percentage of the time they might have this aberration.
So today I’ll be talking about some cases, one of which we have a patient who had PD-L1 expression indicative of a marker for immunotherapy, as well as a BRAF v600e DNA mutation which is typically seen in melanoma and other types of cancers and thyroid cancers...
I think we’ve progressed from an era of knowing diseases like chronic myeloid leukemia, where you have a specific Philadelphia chromosome positive driven disease which is present in 95% of the disease, it’s really looking at more patients on an individual basis and figuring out and what percentage of the time they might have this aberration.
So today I’ll be talking about some cases, one of which we have a patient who had PD-L1 expression indicative of a marker for immunotherapy, as well as a BRAF v600e DNA mutation which is typically seen in melanoma and other types of cancers and thyroid cancers.
But this is a patient from four years ago and essentially this patient was able to go on immunotherapy and achieve a complete response and was doing well for years, and normally this would have been somebody with widely spread metastatic, anaplastic disease, and survival would not have been estimated in years.
